KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells $71,231.20 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 5,296 shares of the firm’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $13.45, for a total transaction of $71,231.20. Following the sale, the insider owned 131,831 shares in the company, valued at approximately $1,773,126.95. This trade represents a 3.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

KalVista Pharmaceuticals Stock Up 6.2%

NASDAQ:KALV traded up $0.82 during midday trading on Wednesday, hitting $14.10. The company had a trading volume of 1,928,887 shares, compared to its average volume of 933,997. The company has a market capitalization of $712.70 million, a PE ratio of -3.58 and a beta of -0.04. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.30 and a 52-week high of $17.28. The stock’s fifty day moving average price is $12.03 and its 200-day moving average price is $12.86.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.96) by $0.04. The firm had revenue of $13.69 million for the quarter, compared to the consensus estimate of $6.03 million. As a group, research analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Analyst Upgrades and Downgrades

KALV has been the subject of several research reports. JMP Securities upped their target price on KalVista Pharmaceuticals from $27.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Friday, September 12th. Citigroup reaffirmed a “market outperform” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, October 8th. Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, September 12th. Finally, Citizens Jmp decreased their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Tuesday, November 11th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $26.63.

Institutional Trading of KalVista Pharmaceuticals

Several large investors have recently modified their holdings of the business. Earned Wealth Advisors LLC purchased a new position in KalVista Pharmaceuticals during the 1st quarter valued at about $44,000. BNP Paribas Financial Markets lifted its holdings in KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 1,292 shares during the period. CWM LLC grew its position in shares of KalVista Pharmaceuticals by 12,636.1% in the 1st quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company’s stock worth $53,000 after buying an additional 4,549 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of KalVista Pharmaceuticals during the third quarter valued at approximately $55,000. Finally, Wolverine Asset Management LLC purchased a new position in shares of KalVista Pharmaceuticals during the third quarter valued at approximately $57,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).